Everest Medicines' Partner Calliditas Presents Nefecon Data at ERA-EDTA Congress

The presentations showed data and analyses from the NefIgArd Phase 3 clinical trial evaluating Nefecon in patients with IgA nephropathy (IgAN). The study m...

 June 21, 2023 | News

Jadeite Medicines Granted Orphan Drug Designation and Initiates Phase 3 Trial for Odevixibat in PFIC by Japanese Ministry of Health

This Phase 3 trial will evaluate the efficacy and safety of an oral dosage of odevixibat in Japanese PFIC patients. Odevixibat is marketed by Ipsen Pharma ...

 June 21, 2023 | News

Cytiva launches 2023 Biopharma Resilience Index

Industry leaders rate capabilities in five key areas: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government poli...

 June 20, 2023 | Analysis

C2 PHARMA Receives Approval for Digoxin China DMF, Becoming China’s Only European Supplier of This API

 C2 Pharma the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the appro...

 June 14, 2023 | News

Thermo Fisher Scientific Expands Sterile Drug Facility in Singapore, Strengthening Asia-Pacific BioPharma Market

Thermo Fisher Scientific, a global leader in serving science, announces the expansion of its sterile drug facility in Singapore, marking a significant mile...

 June 02, 2023 | Influencers

Pfizer's PAXLOVID™ FDA-approved for high-risk adults with severe COVID-19

PAXLOVID is the first FDA-approved oral treatment for COVID-19; has been authorized for emergency use since December 2021 Approval is based on the total...

 May 29, 2023 | News

Antengene's ATG-022 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases o...

 May 24, 2023 | News

Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region

Thermo Fisher Scientific, the world leader in serving science, has opened a new sterile drug facility in Singapore that will better enable customers to del...

 May 19, 2023 | News

Antengene Announces NDA Submission for XPOVIO® in Indonesia

"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...

 May 17, 2023 | News

Cytiva and Pall Life Sciences merge to form a comprehensive solutions provider for biotechnology challenges, with focus on innovation and digitalization

Discover how the combined technical expertise, talent, and portfolio offerings of these two distinguished brands are driving the next generation of medicin...

 May 12, 2023 | News

Ascletis approved for Phase IIa clinical trial of ASC10 for RSV infection in China

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Do...

 May 09, 2023 | News

Bliss Biopharmaceutical Collaborates with Eisai for Clinical Trial of BB-1701 with Strategic Option

This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-...

 May 08, 2023 | News

EirGenix's Breast Cancer Biosimilar EG1206A Meets Phase 1 Trial Goals

Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show that the main test indicators have met the pharmacokinetics...

 May 08, 2023 | News

Formosa Pharmaceuticals and AimMax Therapeutics Submit NDA to US FDA for APP13007 for Post-Operative Pain and Inflammation after Ocular Surgery.

This proprietary homogeneous nanosuspension has a solution-like appearance which offers great comfort to the eyes and enhanced drug penetration into ocular...

 May 05, 2023 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in